Custom Antibody Generation
Build Bioanalytical Assays You Can Count On
Develop and execute bioanalytical assays with confidence when you rely on the proven expertise of Bio-Rad’s scientists for custom anti-drug monoclonal antibodies.Start a Conversation with a Specialist
When the assays you develop are being used to make critical decisions on which therapeutic antibody candidate to advance into the clinic, or are needed to ensure the safety and quality of a biologic during clinical development and manufacturing, you need to be confident in their robustness.
For ligand binding assays (LBAs) such as pharmacokinetic (PK) assays or anti-drug antibody (ADA) assays, the quality of your antibody reagents is critical to your confidence in the performance of your assays. Having highly specific, high affinity and well-characterized antibodies enables development of robust and sensitive assays, leading to data you can rely on.
And, if there is batch-to-batch variability in antibody performance, such as with polyclonal antibodies, you can end up spending a great deal of time in reagent qualification, with no assurance that you’ll have critical quality reagents when you need them.
With custom recombinant monoclonal anti-idiotypic antibody generation from Bio-Rad, you get fast, development of highly specific antibodies that you can rely on throughout the lifecycle of your assay. You also get expert support from a scientific team that has been making recombinant anti-idiotypic antibodies and advancing recombinant antibody production technology1 for over a decade.
Discover Your Next Biotherapeutic Lead
Find clinical-quality candidates in industry-leading timelines with the Pioneer Antibody Discovery Platform. Using one of the largest fully human synthetic phage display libraries in existence, we can deliver your next lead.Contact a Pioneer Specialist
Did you know?
The US FDA approved its 100th monoclonal antibody product in April of 2021, 35 years after approval of the first monoclonal antibody in 1986.2 The 100th monoclonal antibody is the PD1 blocker dostarlimab, brought to the market by GlaxoSmithKline.
How Our Antibodies Give You Confidence In Your Assays
Our specialized service for custom anti-idiotypic antibody generation delivers high affinity, fully human anti-drug antibodies ideal for use in PK bridging ELISAs and as a reference standard in ADA assays.
Our custom service offers the following:
- Antibodies to your biotherapeutic, selected and dispatched in 3 months
- Choose monovalent, bivalent and Ig-like formats for testing at the outset
- 100% success rate for inhibitory, paratope-specific antibodies
- Generation of noninhibitory and drug-target complex antibodies
- Conversion to full immunoglobulin with a choice of isotype (IgG1, IgG2, IgG3 IgG4, IgA, IgE, IgM)
- Site-directed conjugation with consistent degree of labeling using SpyTag technology
- Antibodies sequenced for long-term security of supply
- Anti-idiotypic antibody
- Detects free drug
- Anti-idiotypic antibody
- Not paratope-specific
- Not inhibitory
- Detects total drug (free, partially bound, fully bound)
- Drug target complex-specific
- Not inhibitory
- Detects bound drug exclusively
Key Applications for Anti-idiotypic Antibodies
Discover how recombinant monoclonal anti-idiotypic antibodies are generated at Bio-Rad, our unique capabilities for developing antibodies against drug-target complexes, and how our antibodies can be used to develop highly specific and sensitive PK and ADA assays.
Recombinant Anti-idiotypic Antibodies in Ligand Binding Assays for Antibody Drug Development Stefan Harth and Christian Frisch. Methods Mol Biol. 2021;2261:291-306.
Generation by phage display and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics. Harth S. et al. MAbs. 2019 Jan;11(1):178-190. doi: 10.1080/19420862.2018.1538723. PMID: 30516449; PMCID: PMC6343800.
Recombinant Anti-idiotypic Antibodies in Ligand Binding Assays for Antibody Drug Development. Stefan Harth and Christian Frisch. Methods Mol Biol. 2021;2261:291-306.
Learn how SpyTag technology has been incorporated with custom recombinant antibody generation to make "TrailBlazer Antibodies".
Learn how to secure high quality, critical antibody reagents early in the development lifecycle, and avoid the frustrations and risks associated with assay development failure.
Developing biotherapeutic antibodies is a complex and lengthy process, but there are key assays to use when testing candidates. We offer some essential advice.
What to do when your antibody development project fails? We look at how to overcome challenges in therapeutic antibody discovery.
Learn the key differences between library formats (immune, naïve, synthetic, and semi-synthetic) and find out the best source for your next discovery project.
Discover how anti-idiotypic antibodies can help overcome the challenges involved in the development of bioanalytical assays to monitor antibody drug candidates.
Phage display libraries offer a powerful approach to biotherapeutic discovery. We explain what they are and the recent developments that you can benefit from.
Learn how the generation of anti-idiotypic antibodies and other high specificity tool antibody critical reagents are made to support PK assay design.
- Harth S, Ten Haaf A, Loew C, Frisch C, Knappik A. Generation by phage display and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics. mAbs. 2019;11(1):178-190. doi:10.1080/19420862.2018.1538723
- Mullard A. FDA approves 100th monoclonal antibody product. Nat Rev Drug Discov. 2021;20(7):491-495. doi:10.1038/d41573-021-00079-7
Ready to learn how Bio-Rad can deliver custom antibodies ideal for PK and ADA assays? Our scientists are here to help.Start a Conversation with a Specialist
Discover More Therapeutic Antibody Development Solutions
Move faster and make more informed decisions with products, services, and expert scientific support from antibody discovery to IND.
Streamline cell line characterization using less sample with ddPCR technology.
Maximize productivity with robust, automation-ready high speed flow cytometry.
Find resins for challenging purifications using the help of our expert purification scientists.